131,514 research outputs found
Weatherall, V D, VX144935
No full textThis record was harvested from a previous catalogue system and will be withdrawn in 2025. Information in this record may be superseded or incomplete. Visit this record in UMA's new catalogue at: https://archives.library.unimelb.edu.au/nodes/view/424533Surname: WEATHERALL. Given Name(s) or Initials: V D. Military Service Number or Last Known Location: VX144935. Missing, Wounded and Prisoner of War Enquiry Card Index Number: 52314.252444
Item: [2016.0049.56794] "Weatherall, V D, VX144935
On the Status of the Geodesic Principle in Newtonian and Relativistic Physics
No full textA theorem due to Bob Geroch and Pong Soo Jang ["Motion of a Body in General Relativity." Journal of Mathematical Physics 16(1), (1975)] provides a sense in which the geodesic principle has the status of a theorem in General Relativity (GR). I have recently shown that a similar theorem holds in the context of geometrized Newtonian gravitation (Newton-Cartan theory) [Weatherall, J. O. "The Motion of a Body in Newtonian Theories." Journal of Mathematical Physics 52(3), (2011)]. Here I compare the interpretations of these two theorems. I argue that despite some apparent differences between the theorems, the status of the geodesic principle in geometrized Newtonian gravitation is, mutatis mutandis, strikingly similar to the relativistic case
Wellcome Witnesses to Twentieth Century Medicine: Volume 1
No full textAnnotated and edited transcript of four Witness Seminars. Introduction by E M Tansey First published by the Wellcome Trust, 1997. ©The Trustee of the Wellcome Trust, London, 1997.In Volume One (Occasional Publication no. 4, 1997).All volumes are freely available online at: www.history.qmul.ac.uk/research/modbiomed/wellcome_witnesses/Annotated and edited transcript of four Witness Seminars. Introduction by E M Tansey.Annotated and edited transcript of four Witness Seminars. Introduction by E M Tansey.Annotated and edited transcript of four Witness Seminars. Introduction by E M Tansey.Annotated and edited transcript of four Witness Seminars. Introduction by E M Tansey.Four Witness Seminar transcripts of meetings held between 1993 and 1996: ‘Technology Transfer in Britain: The case of Monoclonal Antibodies’ (E M Tansey and P P Catterall, eds); ‘Self and Non-Self: A History of Autoimmunity’ (E M Tansey, S V Willhoft and D A Christie, eds); ‘Endogenous Opiates’ (E M Tansey and D A Christie, eds); ‘The Committee on Safety of Drugs’ (E M Tansey and L A Reynolds, eds). Introduction by E M Tansey, ‘What is a Witness Seminar’, separate index for each meeting. Tansey E M, Catterall P P, Christie D A, Willhoft S V, Reynolds L A. (eds) (1997) Wellcome Witnesses to Twentieth Century Medicine, volume 1. London: The Wellcome Trust.The Wellcome Trust is a registered charity, no. 210183
MeSH term explosion and author rank improve expert recommendations
No full textInformation overload is an often-cited phenomenon that reduces the productivity, efficiency and efficacy of scientists. One challenge for scientists is to find appropriate collaborators in their research. The literature describes various solutions to the problem of expertise location, but most current approaches do not appear to be very suitable for expert recommendations in biomedical research. In this study, we present the development and initial evaluation of a vector space model-based algorithm to calculate researcher similarity using four inputs: 1) MeSH terms of publications; 2) MeSH terms and author rank; 3) exploded MeSH terms; and 4) exploded MeSH terms and author rank. We developed and evaluated the algorithm using a data set of 17,525 authors and their 22,542 papers. On average, our algorithms correctly predicted 2.5 of the top 5/10 coauthors of individual scientists. Exploded MeSH and author rank outperformed all other algorithms in accuracy, followed closely by MeSH and author rank. Our results show that the accuracy of MeSH term-based matching can be enhanced with other metadata such as author rank
Going Beyond Counting First Authors in Author Co-citation Analysis
No full textThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
Questions asked and answered in pilot and feasibility randomized controlled trials
No full textAbstract Background In the last decade several authors have reviewed the features of pilot and feasibility studies and advised on the issues that should be addressed within them. We extend this literature by examining published pilot/feasibility trials that incorporate random allocation, examining their stated objectives, results presented and conclusions drawn, and comparing drug and non-drug trials. Methods A search of EMBASE and MEDLINE databases for 2000 to 2009 revealed 3652 papers that met our search criteria. A random sample of 50 was selected for detailed review. Results Most of the papers focused on efficacy: those reporting drug trials additionally addressed safety/toxicity; while those reporting non-drug trials additionally addressed methodological issues. In only 56% (95% confidence intervals 41% to 70%) were methodological issues discussed in substantial depth, 18% (95% confidence interval 9% to 30%) discussed future trials and only 12% (95% confidence interval 5% to 24%) of authors were actually conducting one. Conclusions Despite recent advice on topics that can appropriately be described as pilot or feasibility studies the large majority of recently published papers where authors have described their trial as a pilot or addressing feasibility do not primarily address methodological issues preparatory to planning a subsequent study, and this is particularly so for papers reporting drug trials. Many journals remain willing to accept the pilot/feasibility designation for a trial, possibly as an indication of inconclusive results or lack of adequate sample size.</p
"Closing the R&D Gap, Evaluating the Sources of R&D Spending"
No full textBoth spending and tax policies have been implemented in the United States with the goal of stimulating private sector research and development (R&D). Karier questions whether current R&D policy, especially the research and experimentation tax credit, can contribute to closing the gap between nondefense expenditures on R&D in the United States and such expenditures in other countries, such as Japan and Germany. He also explores possible changes to our current R&D policy to make it more effective.
D. J. WEATHERALL - PUBLISHED WORKS (*Major Works) from SIR DAVID JOHN WEATHERALL. 9 March 1933 — 8 December 2018
No full textSir David Weatherall was the outstanding, internationally recognized, clinician scientist of his generation. His lifelong interest in the haemoglobinopathies first came from studying a child that he recognized as having beta thalassaemia while working as an army physician in Malaya. His interest in these diseases further developed as he undertook his PhD in the Department of Haematology under the supervision of Lockard Conley and Victor McKusick in Baltimore. There, together with John Clegg (FRS 1999), he developed the technology to directly measure the synthesis of the alpha and beta globin chains of haemoglobin, and his subsequent work at the University of Liverpool showed that thalassaemia resulted from imbalanced globin chain synthesis. Importantly, using the globin genes as their model, David's laboratory went on to make many of the first discoveries of how expression of the globin genes and mammalian genes in general could be perturbed to cause human genetic diseases. As professor of medicine in Oxford, he established one of the first institutes to develop the use of molecular biology in medicine and he trained many of the world's leading clinician scientists in this area of biomedical research. He also established worldwide networks to apply molecular biology to the haemoglobinopathies and infectious diseases, making a unique contribution to global medicine. He had outstanding qualities as a clinician, a scientist, and a leader, all of which he achieved with great humility and humanity
Optimal management of ß thalassaemia intermedia
No full textOur understanding of the molecular and pathophysiological mechanisms underlying the disease process in patients with β thalassaemia intermedia (TI) has substantially increased over the past decade. The hallmark of disease process in patients with TI includes ineffective erythropoiesis, chronic haemolytic anaemia, and iron overload. There are a number of options currently available for managing patients with TI including splenectomy, transfusion therapy, iron chelation therapy, modulation of fetal haemoglobin production, and several other agents targeting specific clinical complications. Limited studies assessed the efficacy and safety of these modalities; hence, there are currently no clear guidelines for managing patients with TI. Until solid evidence-based guidelines are available, individualised treatment should be entertained
- …
